/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Minus One
  2. The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health
The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health

Minus One · Sep 24, 2026

Guardant Health CEO Helmy Eltoukhy on his journey from engineering to biotech and the future of blood tests for detecting thousands of diseases.

A PhD Founder Can De-Risk a Startup by Viewing it as a 'Pascalian Wager'

Guardant's founder viewed his first startup as a low-risk bet. Even if it failed, the experience and 'CEO' title on his resume would likely land him a better corporate job than he could get otherwise. The perceived risk of entrepreneurship is often overestimated.

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health thumbnail

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health

Minus One·2 months ago

Guardant's 'Iterative March' to Early Cancer Detection Began with a Simpler Market

Instead of tackling their grand vision head-on, Guardant started with a more solvable problem: therapy selection for late-stage cancer. They planned a roadmap to scale their technology 10x at each step, progressively unlocking larger and more complex markets.

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health thumbnail

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health

Minus One·2 months ago

In Healthcare, Business Model Innovation Outweighs Technological Superiority

Guardant's co-CEO argues that in complex fields like diagnostics, success hinges more on innovating the business model than the core technology. Superior tech fails if it doesn't align with the unique economic incentives where the user isn't the payer.

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health thumbnail

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health

Minus One·2 months ago

Guardant's 'Everything Test' Is Powered by Epigenomics, Not Just Genomics

Genomics is useful for cancer but misses common diseases like diabetes or autoimmune disorders that don't alter DNA. Guardant's shift to epigenomics—the 'software' running on the DNA—allows them to detect these other diseases, vastly expanding their market.

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health thumbnail

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health

Minus One·2 months ago

Guardant's Genius Is Getting Paid to Build Its Proprietary Data Moat

The biggest challenge in healthcare AI is acquiring labeled data. Guardant's business model is structured to not only generate a massive proprietary dataset of patient samples and outcomes but to get paid by insurers and pharma to do so, creating a self-funding data flywheel.

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health thumbnail

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health

Minus One·2 months ago

Guardant Used Pharma Deals as Non-Dilutive Funding and a Leading Market Signal

Initially seen as a distraction, pharma partnerships became a source of high-margin, non-dilutive capital for Guardant. More importantly, buying signals from pharma served as a leading indicator for future clinical demand, de-risking their product roadmap.

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health thumbnail

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health

Minus One·2 months ago

Innovation Thrives by Applying Proven Ideas in the 'Valleys' Between Disciplines

Breakthroughs often come from taking a concept from a well-understood field, like electrical engineering, and applying it to a less understood one, like biology. This cross-pollination is one of the most efficient paths to innovation.

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health thumbnail

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health

Minus One·2 months ago

Guardant Health Unlocked 10x Improvements By Framing Biology as an Engineering Problem

Instead of accepting biological limits, Guardant treated challenges like low DNA yield and high sequencing error rates as systems engineering and information processing problems. This reframing allowed for systematic, quantifiable solutions that competitors missed.

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health thumbnail

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health

Minus One·2 months ago

Guardant Lost 18 Months of Market Share By Throttling Growth During a PMF Surge

Faced with high burn from rapid sales with slow reimbursement, Guardant throttled its sales team. The co-CEO now calls this the 'wrong decision,' as it halted momentum, cost them significant market share, and gave competitors time to catch up.

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health thumbnail

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health

Minus One·2 months ago

Current AI for Biology Is Overhyped Because Its Training Data Is Too Low-Resolution

Guardant's co-CEO is skeptical of many AI-in-biology efforts because the underlying public data is often 'very under sampled.' These low-resolution datasets miss the rare signals that differentiate cells, causing AI models to learn from noise rather than true biological drivers of disease.

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health thumbnail

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health

Minus One·2 months ago